Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Blog

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

October 15, 2021

Our teaming agreement with OMNY Health to support breakthrough research using the power of real world data and AI

We are delighted to share the news today that Sensyne and leading US-based real world data company OMNY Health will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research. 

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said: “OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”

Blog

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

October 15, 2021

Our teaming agreement with OMNY Health to support breakthrough research using the power of real world data and AI

We are delighted to share the news today that Sensyne and leading US-based real world data company OMNY Health will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research. 

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said: “OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”

Blog

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

October 15, 2021

Our teaming agreement with OMNY Health to support breakthrough research using the power of real world data and AI

We are delighted to share the news today that Sensyne and leading US-based real world data company OMNY Health will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research. 

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said: “OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”

Blog

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

Our teaming agreement with OMNY Health to support breakthrough research using the power of real world data and AI

We are delighted to share the news today that Sensyne and leading US-based real world data company OMNY Health will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research. 

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said: “OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”

Arrange to meet us
Blog

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

October 15, 2021

Our teaming agreement with OMNY Health to support breakthrough research using the power of real world data and AI

We are delighted to share the news today that Sensyne and leading US-based real world data company OMNY Health will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research. 

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said: “OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”